SOMERSET, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO, CCLDP), a leader in healthcare technology solutions for medical practices and health systems nationwide, will release its financial results for the second quarter ended June 30, 2023 before the market opens on Thursday, August 3, 2023. The Company will follow with a conference call for investors at 8:30 a.m. Eastern Time.
The live webcast of the conference call and related presentation slides can be accessed at ir.carecloud.com/events. An audio-only option is available by dialing 416-764-8658 and referencing "CareCloud Second Quarter 2023 Earnings Call." Investors who opt for audio-only will need to download the related slides at ir.carecloud.com/events.
A replay of the conference call and related presentation slides will be available approximately one hour after conclusion of the call at the same link. An audio-only option can also be accessed by dialing 412-317-6671 and providing access code 83486791.
About CareCloud
CareCloud (Nasdaq: CCLD, CCLDO, CCLDP) brings disciplined innovation to the business of healthcare. Our suite of technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows and improve the patient experience. More than 40,000 providers count on CareCloud to help them improve patient care while reducing administrative burdens and operating costs. Learn more about our products and services including revenue cycle management (RCM), practice management (PM), electronic health records (EHR), business intelligence, telehealth and patient experience management (PXM) at www.carecloud.com.
Follow CareCloud on LinkedIn, Twitter and Facebook.
For additional information, please visit our website at www.carecloud.com. To listen to video presentations by CareCloud’s management team, read recent press releases and view the latest investor presentation, please visit ir.carecloud.com.
SOURCE CareCloud
Company Contact:
Bill Korn
Chief Strategy Officer
CareCloud, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact:
Asher Dewhurst
ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Inquiries:
Alexis Feinberg
ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$3.52 |
Daily Change: | 0.34 10.69 |
Daily Volume: | 1,852,875 |
Market Cap: | US$148.970M |
August 05, 2025 August 04, 2025 July 17, 2025 June 02, 2025 May 06, 2025 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load